Literature DB >> 9285495

Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown.

A Pfeiffer1, J Spranger, R Meyer-Schwickerath, H Schatz.   

Abstract

Chronic hyperglycemia may cause growth factor alterations that are likely to participate in tissue remodeling typical for diabetic late complications. However, few details of such events are known. The ocular vitreous fluid allows studies of growth factor levels in human eyes (after vitrectomy). The vitreous is highly inert and protected by the blood-retina barrier and thus probably reflects growth factor production by the normal retina. Vitreous from patients with proliferative diabetic retinopathy (PDR) was compared with vitreous obtained from patients with nonproliferative eye disease and with vitreous from patients without diabetes but with marked neovascular proliferations due to ischemia. This design permits us to distinguish diabetes-related from non-diabetes-related alterations. Insulin-like growth factor I (IGF-I), IGF-II, IGF binding protein 2 (IGFBP-2), and IGFBP-3 were elevated 3- to 13-fold in nondiabetic retinal ischemia and 1.5- to 3-fold in PDR, indicating that the changes were not restricted to diabetes. These changes may partially be explained by leakage of serum into the vitreous, since IGFs and IGFBPs are 20- to 50-fold higher in serum than in vitreous, and vitreous protein content was 1.5-fold elevated in PDR subjects and 5-fold in ischemia patients compared with control subjects. TGF-beta is a proposed antiangiogenic factor in the eye. TGF-beta2 was the predominant subtype in vitreous, and its total amount was not altered in PDR patients. More importantly, the active fraction of TGF-beta was decreased by 30 and 70% in PDR and nondiabetic retinal ischemia patients, respectively. Since plasmin may control TGF-beta activation, the serum protein alpha2-antiplasmin was measured and found to be significantly elevated to 150 and 250% of control values in PDR and ischemia patients, respectively. Thus, influx of serum proteins due to microvascular disturbances and hypoxia is proposed as a possible cause for vitreous alterations of IGF-I and of active TGF-beta. These changes seem to occur late in the sequence of events leading to PDR and are not specific for diabetes, but they were also observed in other diseases characterized by retinal hypoxia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285495     DOI: 10.2337/diab.46.2.s26

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  18 in total

1.  Defective retinal vascular endothelial cell development as a consequence of impaired integrin αVβ8-mediated activation of transforming growth factor-β.

Authors:  Thomas D Arnold; Gina M Ferrero; Haiyan Qiu; Isabella T Phan; Rosemary J Akhurst; Eric J Huang; Louis F Reichardt
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

2.  Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization.

Authors:  Alexander V Ljubimov; Sergio Caballero; Annette M Aoki; Lorenzo A Pinna; Maria B Grant; Raquel Castellon
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-12       Impact factor: 4.799

3.  Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration.

Authors:  Thomas Bertelmann; Marta Spychalska; Laura Kohlberger; Stefan Strodthoff; Michael Witteborn; Nadia Kicova; Ulrich Sachs; Sebastian Irle; Stefan Mennel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-12       Impact factor: 3.117

4.  Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion.

Authors:  Yukihiko Suzuki; Mitsuru Nakazawa; Kaori Suzuki; Hitoshi Yamazaki; Yasuhiro Miyagawa
Journal:  Jpn J Ophthalmol       Date:  2011-05-03       Impact factor: 2.447

5.  Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells.

Authors:  S M Wileman; N A Booth; N Moore; B Redmill; J V Forrester; R M Knott
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

6.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

7.  Vitreous polyamines spermidine, putrescine, and spermine in human proliferative disorders of the retina.

Authors:  R Nicoletti; I Venza; G Ceci; M Visalli; D Teti; A Reibaldi
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

8.  Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice.

Authors:  Jun Su; Pamela A Lucchesi; Romer A Gonzalez-Villalobos; Desiree I Palen; Bashir M Rezk; Yasuhiro Suzuki; Hamid A Boulares; Khalid Matrougui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-05-15       Impact factor: 8.311

9.  Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice.

Authors:  Souad Belmadani; Desiree I Palen; Romer A Gonzalez-Villalobos; Hamid A Boulares; Khalid Matrougui
Journal:  Diabetes       Date:  2008-03-04       Impact factor: 9.461

10.  Insulin-like growth factor-1 activates PI3K/Akt signalling to protect human retinal pigment epithelial cells from amiodarone-induced oxidative injury.

Authors:  Rifang Liao; Fengxia Yan; Zhuanping Zeng; Haitao Wang; Kaifeng Qiu; Jinying Xu; Wenhua Zheng
Journal:  Br J Pharmacol       Date:  2017-12-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.